Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Gentronix Unveils New Corporate Identity and Website

Published: Tuesday, March 26, 2013
Last Updated: Tuesday, March 26, 2013
Bookmark and Share
Gentronix offers GreenScreen® HC and BlueScreen™ HC assays.

Gentronix has revealed a new corporate identity and re-designed website. The new identity has been developed to reflect how the company has evolved into a mainstream provider of early screening in vitro genetic toxicology assays, and mechanistic follow-up, to a range of business sectors including pharmaceuticals, chemicals, agrochemicals, flavours fragrances and taste enhancers, and the personal care and consumer product industries.

In addition to classical in vitro early screening assays, such as the Ames bacterial mutation reversal and Micronucleus tests, Gentronix offers their proprietary GreenScreen® HC and BlueScreen™ HC assays.

The company also supports clients in the development of de-risking strategies and carrying out further assays to determine the mechanism and causes of positive genotox screening results.

As such, Gentronix has a wealth of knowledge and experience in the field and this is reflected in the new website at www.gentronix.co.uk which hosts content on the science of genotoxicity, regulations for each industry sector, screening procedures, as well as links to an extensive range of peer reviewed papers.

John Nicholson, CEO at Gentronix, comments, “In recent years we have greatly diversified our range of genotoxicity screening product and service offerings. We also provide advice on dealing with positive results and are able to offer a variety of further assays and strategies to help understand the mechanism of genotoxicity. This updating of our corporate identity has been undertaken to better reflect this. These are exciting times for Gentronix, and we feel that the new identity and website helps us to build on our strong foundations to move the business forward.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gentronix Awarded Grant of £147,552 by MRC and Technology Strategy Board
Company awarded grant from the Biomedical Catalyst programme for an epigenetic based screening assay feasibility study.
Thursday, December 20, 2012
Improved In Vitro Genotoxicity Testing to Reduce Animal Testing
In conjunction with the University of Manchester, Gentronix has been granted a research award of £133,024.
Thursday, August 10, 2006
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!